Home- Research
- Conferences
- Workshops & Training
- Program
- Overview
- *Innovation Cafe
- Drug Safety
- Counterfeit Drugs
- Valuation & Auditing
- Drug Discovery Innovation
- Drug Development
- Complex Systems & Org. Development
- Semantic Web
- R&D Knowledge Management
- Abstracts
- Speakers
- Allemand, P
- Barrett, J
- Gardner, S
- Gates, P
- Gibbs, A
- Hardy, B
- Henrick, K
- Jautelat, R
- Jordis, U
- Kanagy, J
- Liebman, M
- Montano, B
- Newman, V
- Polsky-Newman, R
- Scoffin, R
- Sharp, M
- Spitzner, J
- Starry, S
- Weintraub, H
- Wikel, J
- Molecular Medicine
- Nanobiotech
- Personalised Medicine
- Exhibition
- Registration
- About
- Overview
- Contact
- Support
- Schedule
|
|
|
|
|
|
|
|
|
| Ulrich Jordis, Vienna University of Technology |
|
Curriculum Vitae of Ulrich Jordis
Date of birth: 17/11/1946
Nationality: Austrian
Education
Vienna University of Technology
Diploma Thesis 1972
Ph.D. in Organic Chemistry 1974
"Habilitation" (=lecturing qualification) 1989
Professional Appointments
1973-1974 Inst. Organic Chemistry, Vienna, Teaching/Research Assistant
September 1975- August 1976 Massachusetts Institute of Technology (M.I.T.) Fulbright Research Fellow (Post-Doc with Sidney M. Hecht: synthesis of the bithiazole-part of bleomycin,pyrazolo[3,4-e]pyrimidines)
1983 (June - September) University of Illinois at Urbana IL, Fulbright Research Associate with Prof. Nelson J. Leonard
1976-1989 (with 4 months sabbatical in 1983) Vienna University of Technology, Research Assistant
since 1989 Vienna University of Technology, Associate Professor
Other professional activities
Head of the working-group "Computers in Chemistry" of the Austrian Chemical Society (1994-2002)
Austrian Coordinator of COST D 16 Action (Combinatorial Chemistry) (since 1999)
Current research interests
Synthesis of Galanthamine-type natural products and analogs, combinatorial chemistry and solid phase synthesis, chemistry databases, modified nucleosides as potential antivirals, natural products and analogs as immunostimulants, bridged piperazines as building blocks for the pharmaceutical industry, HPLC analysis of drugs and drug metabolites, synthesis of drug metabolites, GC-MS analysis of prehistorical wood tar pitches including samples from the Tyrolianice-man.
Expert in Chemistry Databases.
Consulting / pharmaceutical companies
Chemie Linz AG (Austria, 1979-1991, co-operation in the quinolone field)
American Home Products (USA, peviously Cyanamid, Lederle / Pearl River)
1982 - 1991: co-operation in the quinolone field
1991 - 1996: co-operation in the field ov antiviral agents
Sanochemia Pharmazeutika AG (Austria, 1992-2003)
Galanthamine industrial synthesis, anti-Alzheimer agents.
Pharmanalyt (Austria, 1998 to present)
Trenka Pharm. Co. (Austria, 1998 to present)
Byk Goulden (Germany, 1999 – 2000)
Eburon Organics (Belgium, 2000 – since 2001 Head of Research and Development Unit)
Iconix Pharmaceutical (USA, 2001-2005)
Green Hills Biotechnology (Austria, 2003 to present)
Galanthos (new company in foundation stage) Germany, 2005
Onepharm (co-founder and CSO of new company) Austria, 2005
|
|
|
|
Molecular Architecture to Prepare Structures with Desired Properties: The Integration of Databases and Software into the Day-to-Day Practice of a Medicinal Chemist
Ulrich Jordis, Vienna University of Technology
The talk will give examples of the planning of the synthesis of new bioactive compounds, typically targeted for their expected pharmacological properties. This requires first of all the assessment of the novelty which is performed by a combination of the use of Chemical Abstracts (via SciFinder) and Beilstein (via Beilstein Commander). Marpat is used to identify claims of patents that might cover virtual compounds. Reactions are planned using Chemical Abstracts as well as various dedicated ISIS reaction databases and DiscoveryGate. The availability of starting materials and reference or test compounds must be known and all the data gathered are stored in local structure and reaction databases. Emphasis will be given to resources available freely on the web. At the end of the day a wealth of data is stored in proprietary databases including electronic notebooks.
|
|
|
|
|
|
|
